Iterum Therapeutics reports Q3 non-GAAP EPS (24c) vs. ($1.20) last year

“With last month’s approval of ORLYNVAH, we have renewed our outreach to potential strategic partners,” said Corey Fishman, Iterum’s Chief Executive Officer. “As the only oral penem antibiotic approved for commercial sale in the U.S. and the potentially first branded uncomplicated urinary tract infection product to enter this underserved market in over 25 years, the value proposition of ORLYNVAH is significant. There is substantial unmet need in the uUTI market due to antibiotic resistance to existing oral antibiotics which is affecting their efficacy, and reinforces the need for new treatment options like ORLYNVAH.”